Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in ReceivablesExchange Rate EffectFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Cyclerion Therapeutics (CYCN) Change in Cash (2019 - 2025)

Cyclerion Therapeutics (CYCN) has 7 years of Change in Cash data on record, last reported at $1.6 million in Q3 2025.

  • For Q3 2025, Change in Cash rose 191.03% year-over-year to $1.6 million; the TTM value through Sep 2025 reached $1.7 million, up 127.2%, while the annual FY2024 figure was -$4.3 million, 25.33% up from the prior year.
  • Change in Cash reached $1.6 million in Q3 2025 per CYCN's latest filing, up from -$633000.0 in the prior quarter.
  • Across five years, Change in Cash topped out at $25.1 million in Q2 2021 and bottomed at -$13.0 million in Q1 2021.
  • Average Change in Cash over 5 years is -$2.8 million, with a median of -$1.7 million recorded in 2024.
  • The widest YoY moves for Change in Cash: up 336.24% in 2021, down 185.5% in 2021.
  • A 5-year view of Change in Cash shows it stood at -$8.5 million in 2021, then increased by 17.78% to -$7.0 million in 2022, then soared by 78.11% to -$1.5 million in 2023, then surged by 123.42% to $360000.0 in 2024, then surged by 333.89% to $1.6 million in 2025.
  • Per Business Quant database, its latest 3 readings for Change in Cash were $1.6 million in Q3 2025, -$633000.0 in Q2 2025, and $407000.0 in Q1 2025.